Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 – Clinical Trial Optional)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for research institutions, universities, hospitals, and nonprofit organizations that conduct biomedical research aimed at translating diagnostic and treatment technologies from academic settings into practical clinical applications. It supports collaborative partnerships between academic researchers and industry partners to accelerate the development and validation of new medical technologies. Applicants must have institutional capacity to conduct clinical research, possess preliminary data demonstrating feasibility, and be able to demonstrate a credible pathway to commercialization or clinical implementation. The program encourages applications from diverse geographic regions and institutions, including minority-serving institutions and emerging research centers. Activities funded include research and development, clinical validation studies (clinical trial component is optional), regulatory pathway planning, and feasibility assessments for translating laboratory innovations into patient-care settings.
Not the right fit? Find grants for your organization in 5 questions →
Program description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.
Who can apply
Eligible applicants
How to apply
Application links
Required documents
- SF-424 (Application for Federal Assistance) and associated forms
- Project Narrative (detailed research plan, translational strategy, and clinical pathway)
- Budget and Budget Justification (detailed for first year; summary for out-years)
- Biosketch for all key personnel (Biographical Sketch Form, NIH format)
- Letters of Support and Commitment from industry partners and collaborating institutions
- Institutional Review Board (IRB) approval documentation or commitment letter (if clinical work is proposed)
- Data Management and Sharing Plan
- Preliminary Data Section (demonstrating feasibility)
- Timeline and Milestone Chart for translation pathway
- Institutional Assurance and Certification documents
- Conflict of Interest disclosure forms
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.394 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$67,679,289
-
$42,479,238
-
$38,139,324
-
$37,552,767
-
$36,939,788
-
$35,037,695
-
$30,393,940
-
$30,179,102
-
$18,390,244
-
$18,143,614
Top States by Funding
- PA 10 awards $135.7M
- WA 7 awards $122.3M
- CA 12 awards $108.0M
- TX 8 awards $92.9M
- OH 5 awards $73.2M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.394). How funding has trended year over year.
| 2024 | $540,918,671 | |
| 2025 | $602,293,691 | |
| 2026 est. | $716,748,079 |
FAQ
What types of organizations are eligible to apply?
Research universities, medical schools, teaching hospitals, nonprofit research institutions, and other entities with strong research infrastructure and institutional support for research are eligible. Academic institutions must partner with industry collaborators, and industry partners may serve as co-applicants or collaborators.
Is a clinical trial required for this application?
No. While the grant title includes "Clinical Trial Optional," applications may focus on early-stage technology translation, preclinical validation, or regulatory pathway development without conducting a full clinical trial. However, applications proposing clinical trials often demonstrate stronger translation potential.
What is the typical funding range and project duration?
R01 awards typically range from $250,000 to $750,000 in direct costs annually, though amounts vary by application scope. Project periods are commonly 3-5 years, with the ability to request competing renewals.
How competitive is this grant?
NIH R01 grants are highly competitive, typically with success rates between 15-25% nationally. Strong preliminary data, feasibility of the research plan, significance of the innovation, and strength of the academic-industry partnership are critical.
When are applications due and how often can I resubmit?
The current application deadline is January 7, 2028. The application window typically opens 6-8 weeks before the deadline. If not funded, applicants may resubmit with responses to reviewer feedback, with new deadlines occurring 3-4 times yearly.
💡 Tips for applicants
- Establish a genuine, complementary academic-industry partnership with clearly defined roles: academic partners lead research innovation while industry contributes expertise in commercialization, manufacturing, and regulatory pathways. Letters of commitment from industry collaborators are essential and carry significant weight in review.
- Lead with strong preliminary data demonstrating proof-of-concept and feasibility. Reviewers want evidence that your technology works in bench or early animal models and that the team has the expertise to move it forward efficiently.
- Develop a clear translational roadmap that articulates specific milestones from current research stage to clinical validation or market pathway. Explain what your team will accomplish, what the next steps are, and what barriers you'll overcome.
- Address commercialization and sustainability realistically. Discuss intellectual property strategy, regulatory pathway (FDA clearance/approval timeline), market potential, and how the technology will ultimately reach patients. This demonstrates understanding of the translation process beyond grant funding.
- Build a diverse, experienced team that includes clinicians, biomedical engineers, industry representatives, and regulatory experts. Letters of support from collaborating institutions and documented institutional commitment strengthen applications and show your organization is invested in the project's success.
⚠️ Common mistakes
Applications often fail when the academic-industry partnership is poorly defined or appears to be a contract research arrangement rather than a genuine collaboration. Reviewers also reject applications lacking sufficient preliminary data or credible evidence of technology feasibility. Additionally, applications that focus narrowly on research without addressing translation milestones, regulatory strategy, or commercialization pathway are seen as insufficiently innovative and translational in scope.
Similar grants
- OPEN Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 – Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed) — National Institutes of Health